This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

This study has been completed.
Information provided by (Responsible Party):
BTG International Inc. Identifier:
First received: June 24, 2009
Last updated: February 19, 2014
Last verified: February 2014
To determine the effect and safety of Varisolve® 0.125% [0.2%]

Condition Intervention Phase
Varicose Veins Drug: Polidocanol Endovenous Microfoam 0.125% Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence

Resource links provided by NLM:

Further study details as provided by BTG International Inc.:

Primary Outcome Measures:
  • Responders to Treatment, Assessed by Duplex Ultrasound [ Time Frame: 8 weeks ]
    Responders; elimination of reflux through the saphenofemoral junction and/or coplete occlusion of the great saphenous vein at 8 weeks, as measured by duplex ultrasound.

Enrollment: 16
Study Start Date: June 2009
Study Completion Date: January 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Varisolve 0.125% Drug: Polidocanol Endovenous Microfoam 0.125%
Polidocanol Endovenous Microfoam 0.125%, single dose
Other Name: Varisolve 0.125%

Detailed Description:
In patients with SFJ incompetence due to reflux of the Great Saphenous Vein (GSV) or major accessory veins, with venous disease manifested by both symptoms and visible varicosities: using duplex ultrasonography, to evaluate the efficacy of Varisolve® 0.125% [0.2%] as assessed by the elimination of SFJ reflux and/or occlusion of the treated vein

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female; age of consent to 75 years
  2. Baseline VEINES-Sym Questionnaire score less than 75 points
  3. Superficial venous disease manifested by both symptoms and visible varicosities
  4. Varicose vein clinical classification CEAP 2 through 5
  5. Incompetence of SFJ (reflux > 0.5 seconds on duplex ultrasonography) associated with incompetence of the great saphenous vein (GSV) or other major accessory vein
  6. Ability to comprehend and sign an informed consent document and complete study questionnaires in English

Exclusion Criteria:

  1. Incompetence of the small saphenous vein (SSV)
  2. Ultrasonographic or other evidence of current or previous deep vein thrombosis, occlusion or incompetence
  3. Leg obesity impairing the ability to access the vein to be treated and/or to follow the post-procedural compression recommendations.
  4. Peripheral arterial disease in the leg to be treated contraindicating post-procedural compression.
  5. Reduced mobility (inability to maintain a brisk walk unaided for a minimum of 5 minutes per hour per day).
  6. Planned prolonged automobile, bus, or air travel within 4 weeks following treatment, unless the patient can walk for at least 5 consecutive minutes every hour during travel.
  7. History of pulmonary embolism or stroke.
  8. Major surgery, prolonged hospitalization or pregnancy within 3 months of screening.
  9. Current anticoagulation therapy (within 7 days of enrollment).
  10. Participation in a clinical study involving an investigational pharmaceutical product or device within the 3 months prior to screening.
  11. Previous treatment in this study or in a previous Varisolve® study.
  12. Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.) or clinically significant laboratory abnormalities.
  13. Known allergic response to polidocanol, or severe and multiple allergic reactions.
  14. Women of childbearing potential not using effective contraception for at least one month prior to study enrollment and/or unwilling to continue birth control until their last study visit.
  15. Pregnant or lactating women.
  16. Current alcohol or drug abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00928421

United States, Washington
Bellevue, Washington, United States
Sponsors and Collaborators
BTG International Inc.
Study Chair: Ellen Evans BTG International Inc.
  More Information

Responsible Party: BTG International Inc. Identifier: NCT00928421     History of Changes
Other Study ID Numbers: VAP.VV014
Study First Received: June 24, 2009
Results First Received: February 19, 2014
Last Updated: February 19, 2014

Keywords provided by BTG International Inc.:
Varicose Veins

Additional relevant MeSH terms:
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Sclerosing Solutions
Pharmaceutical Solutions processed this record on September 21, 2017